apvo436
mAbexperimentalMulti-specific
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 15, 2018 (NCT03647800)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CD3E inhibitor
- Interleukin-3 receptor subunit alphaINHIBITOR
IL3RA inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04973618 | Phase 1 | Jan 31, 2025 | Aptevo Therapeutics |
| NCT06634394 | Phase 1 | Oct 1, 2024 | Aptevo Therapeutics |
| NCT03647800 | Phase 1 | Nov 15, 2018 | Aptevo Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aptevo Therapeutics | For profit | 3 | 3 | 1 | 2018 |
1 organizations
Page 1 / 1